Shaily Engineering Plastics Q4 FY26: PAT up 40%

Shaily Engineering Plastics’ Q4 FY26 results put the spotlight on a sharper mix shift toward healthcare and a marked improvement in profitability. The company reported year-on-year growth in revenue, EBITDA and profit for the quarter ended March 31, 2026, even as it flagged weaker demand trends in its consumer segment across Europe and the US. Healthcare emerged as the key growth driver, supported by the company’s stated positioning as a supply partner in the semaglutide drug ecosystem and its broader focus on drug delivery capabilities.

The company also pointed to a new growth lever in consumer electronics, where it said commercial deliveries to a customer began during Q4 FY26 after multiple quarters of preparation and qualification.

Results date and reporting period

Shaily Engineering Plastics said its Q4 FY26 results were declared on May 19, 2026. The reported quarter covers the period ended March 31, 2026. Alongside quarterly numbers, the company also provided full-year FY26 performance indicators, including consolidated revenue, segment mix, exports contribution and machine utilization.

Q4 FY26 consolidated performance

For Q4 FY26, Shaily reported consolidated revenue of ₹237 crore, compared with ₹218 crore in Q4 FY25, translating into 9% year-on-year growth. EBITDA for the quarter was reported at ₹69 crore, up from ₹55 crore in the year-ago quarter, a 27% year-on-year increase. EBITDA margin for Q4 FY26 was stated at 29.3%, with an expansion of 420 basis points over Q4 FY25.

Profitability also improved. The company reported Q4 FY26 profit after tax (PAT) of about ₹40 crore, compared with about ₹29 crore in Q4 FY25, reflecting roughly 40% year-on-year growth. Reported PAT margin for the quarter was about 17%, with an expansion of 390 basis points versus Q4 FY25.

A separate operating view presented for Q4 FY26 cited net sales of ₹236.82 crore, operating profit (excluding other income) of ₹65.62 crore, and an operating margin of 27.71% (up from 25.02% in Q4 FY25). It also noted employee costs rising to ₹30.21 crore in Q4 FY26 from ₹23.24 crore in Q4 FY25.

Segment performance: healthcare leads, consumer weak

Healthcare was described as the standout segment in Q4 FY26, with segment revenue rising sharply. Q4 FY26 healthcare revenue was reported at ₹113 crore, compared with ₹56 crore in Q4 FY25, implying 110% year-on-year growth. For the full year, healthcare revenue rose 139% to ₹393 crore, and the company stated it contributed 40% of consolidated revenue, up from 21% in FY25.

The consumer segment moved in the opposite direction in Q4 FY26, with revenue at ₹102 crore compared with ₹148 crore in Q4 FY25, a 31% decline. Management attributed this to weaker market demand for home furnishings across Europe and the US. For FY26, consumer revenue was reported at ₹512 crore, down 9%.

Industrial remained a smaller but growing contributor. Q4 FY26 industrial segment revenue was ₹22 crore, up from ₹14 crore in Q4 FY25, a 60% year-on-year rise. For FY26, industrial revenue grew 41% to ₹87 crore, with the company linking the increase to new customer additions and expanding engineering applications.

Consolidated FY26: revenue and operating profile

For FY26, Shaily reported consolidated revenue of ₹991 crore, compared with ₹787 crore in FY25, representing 26% year-on-year growth. Consolidated EBITDA for FY26 was also stated at ₹287.7 crore, with the EBITDA margin expanding to 29.0% (an increase of 630 basis points).

Operational indicators showed improved asset use and export orientation. Machine utilization improved to 47.6% in FY26 from 42.2% in the prior year. Exports contributed around 58% of total revenue in FY26.

Semaglutide and drug-delivery focus

Management described the semaglutide market as one of the fastest-growing drug segments globally and said its positioning as a supply partner in this space is a strategic asset. It also linked healthcare outperformance to multi-year investments in R&D, pen injector platforms and drug delivery capabilities. In this context, the FY26 healthcare mix shift to 40% of consolidated revenue is notable because it changes the earnings profile of the business toward higher-growth medical applications.

Consumer electronics: commercial deliveries begin

The company said it began supplies to a consumer electronics customer during Q4 FY26. It described the business as one it had been preparing and qualifying for over the past several quarters, and said the start of commercial deliveries represented a new growth vector. While revenue contribution was not quantified, the timing places the start of these shipments within the same quarter where healthcare drove headline growth.

Dividend and standalone financial disclosures

For the year ended March 31, 2026, Shaily’s board recommended a final dividend of ₹3 per share (150%), subject to shareholder approval at the upcoming Annual General Meeting. The company also disclosed standalone metrics, reporting standalone revenue from operations of ₹921.20 crore and standalone net profit of ₹161.32 crore for FY26.

Key numbers at a glance

Segment revenue snapshot

Market impact: what the numbers indicate

The reported quarter shows a combination of moderate top-line growth and sharper profitability expansion, supported by a higher contribution from healthcare. With exports contributing about 58% of FY26 revenue, the company remains meaningfully linked to overseas demand cycles, which is consistent with management’s commentary on weaker consumer demand in Europe and the US. At the same time, the healthcare segment’s stated rise to 40% of consolidated revenue in FY26 indicates a structural shift in the revenue base compared with FY25.

Operationally, the improvement in machine utilization to 47.6% in FY26 from 42.2% in the prior year provides context for margin expansion during the year. The rise in employee costs cited for Q4 FY26 also signals ongoing investments aligned with growth initiatives.

Why FY26 matters for investors tracking Shaily

FY26 combined multiple moving parts: a healthcare-led growth phase, a consumer segment that remained under pressure due to weaker demand, and continued momentum in the industrial segment from customer additions and engineering applications. The company’s disclosure on semaglutide supply positioning and pen injector platform investments provides a clear framework for why healthcare revenues rose sharply. Separately, the start of commercial deliveries to a consumer electronics customer in Q4 FY26 adds another operational milestone, even though the company did not quantify its financial contribution.

Conclusion

Shaily Engineering Plastics closed Q4 FY26 with higher revenue and materially better margins, led by a surge in healthcare revenues and supported by improved utilization and an export-heavy mix. The company has also proposed a ₹3 per share final dividend for FY26, subject to shareholder approval at the AGM, and highlighted new commercial deliveries in consumer electronics as an additional growth area.